These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 77051)

  • 1. Immunofluorescence study on thrombolysis with special reference to the patterns of distribution and the contents of fibrin, plasminogen, alpha2-macroglobulin and urokinase in artificial thrombi.
    Hisano S
    Thromb Haemost; 1978 Feb; 39(1):53-60. PubMed ID: 77051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
    Aoki N; Moroi M; Tachiya K
    Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on thrombolysis with streptokinase. IV. Immunofluorescent investigations on the fibrin pattern and the content of plasminogen and of plasma-plasmin-inhibitors in clots and thrombi of various age.
    Gottlob R; el-Nashef B; Donas P; Piza F; Kolb R
    Thromb Diath Haemorrh; 1973 May; 29(2):393-407. PubMed ID: 4586907
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunohistochemical and histochemical investigations on in vivo thrombolysis with urokinase in rabbits.
    Hisano S; Sueishi K; Ishii Y; Tanaka K
    Thromb Haemost; 1979 Jun; 41(4):796-803. PubMed ID: 483251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric fibrinolysis.
    Nilsson IM; Bergentz SE; Hedner U; Kullenberg K
    Thromb Diath Haemorrh; 1975 Nov; 34(2):409-18. PubMed ID: 807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.
    Harpel PC
    J Clin Invest; 1981 Jul; 68(1):46-55. PubMed ID: 6166634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
    Wijngaards G
    Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.
    Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C
    Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.